Clinical trial results:
One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Raltegravir

Summary

EudraCT number	2013-001564-37
Trial protocol	AT
Global end of trial date	17 December 2015

Results information

Result version number	v1 (current)
This version publication date	13 July 2016
First version publication date	13 July 2016

Trial information

Trial identification

Sponsor protocol code	AGMT_HIV1

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02097108
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	AGMT
Sponsor organisation address	Gentzgasse 60/20, Vienna, Austria, 1180
Public contact	Daniela Wolkersdorfer, AGMT, 0043 6626404411, d.wolkersdorfer@agmt.at
Scientific contact	Richard Greil, AGMT, 0043 5725525801, r.greil@salk.at

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 May 2016
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 December 2015
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Primary Objective:
A reduction of > 5% in the plasma concentration of direct LDL cholesterol from baseline to week 12 or > 10% reduction of total cholesterol or reduction of lipid lowering agents is expected. Reduction of lipid lowering agents is defined as reduction due to amelioration of lipid profiles and does not include reduction due to side effects or other toxicity issues.

Protection of trial subjects:

Patients will be assessed at baseline, after 4, 12 and 24 weeks.
At each visit clinical data and blood samples will be collected.
Safety will be monitored by reporting of clinical adverse events and laboratory abnormalities.

Background therapy:

antiretroviral agents other than Protease inhibitor

Evidence for comparator: -

Actual start date of recruitment	02 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 11
Worldwide total number of subjects	11
EEA total number of subjects	11

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	11
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

HIV infected women with hyperlipidemia receiving antiretroviral therapy consisting of at least 2 antiretroviral agents other than protease inhibitor plus a ritonavir-boosted protease inhibitor (PI) for at least the previous 6 months

Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Raltegravir

Arm description:

Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
Patients will be assessed at baseline, after 4, 12 and 24 weeks.

Arm type	Experimental
Investigational medicinal product name	Raltegravir
Investigational medicinal product code	
Other name	ISENTRESS®
Pharmaceutical forms	Coated tablet
Routes of administration	Oral use

Dosage and administration details:

400mg twice daily

Number of subjects in period 1	Raltegravir
Started	11
Completed	9
Not completed	2
Adverse event, non-fatal	1
patient was abroad for 6 months	1

Baseline characteristics

Reporting groups	
Reporting group title	overall trial

Reporting group description: -

Reporting group values	overall trial	Total	
Number of subjects	11	11	
Age categorical Units: Subjects			
Adults (18-64 years)	11	11	
Gender categorical Units: Subjects			
Female	11	11	

End points

End points reporting groups

Reporting group title	Raltegravir

Reporting group description:

Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.
Patients will be assessed at baseline, after 4, 12 and 24 weeks.

Primary: LDL cholesterol reduction

End point title	LDL cholesterol reduction[1]

End point description:

A reduction of > 5% in the plasma concentration of direct LDL cholesterol from baseline to week 12 or > 10% reduction of total cholesterol or reduction of lipid lowering agents is expected. Reduction of lipid lowering agents is defined as reduction due to amelioration of lipid profiles and does not include reduction due to side effects or other toxicity issues.

End point type	Primary

End point timeframe:

12 weeks

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses is provided as this is an one arm, open label, non-comparative study.
In summary, 10 out of 11 patients = 90.9% (95%CI 58.7% - 99.8%) reached the study goal to reduce their cholesterol levels. The null hypothesis of 35% can be rejected (p=0.0001).

End point values	Raltegravir			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: patients	10			

Statistical analyses

No statistical analyses for this end point

Secondary: changes from baseline in total cholesterol

End point title	changes from baseline in total cholesterol

End point description:

To assess changes and from baseline in total cholesterol

End point type	Secondary

End point timeframe:

24 weeks

End point values	Raltegravir			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dl				
arithmetic mean (standard deviation)				
Baseline	247.55 (± 21.07)			
24 weeks	215.7 (± 28.55)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes from baseline in triglycerides

End point title	changes from baseline in triglycerides
End point description: To assess changes from baseline in triglycerides at endpoint	
End point type	Secondary
End point timeframe: 24 weeks	

End point values	Raltegravir			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dl				
arithmetic mean (standard deviation)				
baseline	168.45 (± 57.08)			
24 weeks	83.3 (± 28.94)			

Statistical analyses

No statistical analyses for this end point

Secondary: changes from baseline HDL cholesterol

End point title	changes from baseline HDL cholesterol
End point description: To assess changes from baseline in HDL cholesterol at endpoint	
End point type	Secondary
End point timeframe: 24 weeks	

End point values	Raltegravir			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: mg/dl				
arithmetic mean (standard deviation)				
baseline	58 (± 14.09)			
24 weeks	64 (± 12.75)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All (serious) adverse events occurring during study treatment were collected until 28 days after the end of study treatment.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17.0

Reporting groups

Reporting group title	All patients

Reporting group description: -

Serious adverse events	All patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 11 (9.09%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	All patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 11 (45.45%)		
Investigations			
GOT increased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
GPT increased			
subjects affected / exposed	1 / 11 (9.09%)		
occurrences (all)	1		
Gamma GT increased			

subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1		
Nervous system disorders Headache subjects affected / exposed occurrences (all)	 1 / 11 (9.09%) 1		
General disorders and administration site conditions Fever subjects affected / exposed occurrences (all)	 1 / 11 (9.09%) 1		
Gastrointestinal disorders Constipation subjects affected / exposed occurrences (all) Abdominal pain subjects affected / exposed occurrences (all)	 1 / 11 (9.09%) 1 1 / 11 (9.09%) 1		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	 1 / 11 (9.09%) 1		
Skin and subcutaneous tissue disorders Hair loss subjects affected / exposed occurrences (all)	 1 / 11 (9.09%) 1		
Renal and urinary disorders Pain during emiction subjects affected / exposed occurrences (all)	 1 / 11 (9.09%) 1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported